Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HS 001

Next Previous
Drug Profile

HS 001

Alternative Names: HS-001; HS-001 CS; HS-005; Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension; NN-9003

Latest Information Update: 18 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heartseed Inc.
  • Class Cell therapies; Gene therapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Heart failure

Most Recent Events

  • 31 Mar 2026 Heartseed initiates enrolment in the phase I/II EMERALD trial for Heart failure in Japan (Intracardiac) (NCT07347197)
  • 01 Jan 2026 Heartseed plans a phase I/II EMERALD trial for Heart failure and Ischaemic heart disorders (Intracardiac) in January 2026 (NCT07347197)
  • 11 Sep 2023 Efficacy and adverse events data from a Phase I/II LAPiS trial in Heart failure released by Heartseed

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top